Lorenzo Facila
Overview
Explore the profile of Lorenzo Facila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
991
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rumiz E, Valero E, Fernandez C, Vilar J, Pellicer M, Cubillos A, et al.
PLoS One
. 2024 May;
19(5):e0303284.
PMID: 38743727
Introduction: Complete revascularization (CR) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD), is associated with a reduction in major adverse cardiovascular events (MACE). However, there is...
2.
Bonanad C, Buades J, Leiva J, de la Espriella R, Marcos M, Nunez J, et al.
Front Cardiovasc Med
. 2024 Jan;
10:1225823.
PMID: 38179502
There is an unmet need to create consensus documents on the management of cardiorenal patients since, due to the aging of the population and the rise of both pathologies, these...
3.
Cano J, Bertomeu-Gonzalez V, Facila L, Hornero F, Alcaraz R, Rieta J
Bioengineering (Basel)
. 2023 Dec;
10(12).
PMID: 38136030
Hypertension, a primary risk factor for various cardiovascular diseases, is a global health concern. Early identification and effective management of hypertensive individuals are vital for reducing associated health risks. This...
4.
Santas E, Del Canto I, Cardells I, Minana G, Llacer P, Almenar L, et al.
ESC Heart Fail
. 2023 Dec;
11(2):1258-1262.
PMID: 38115745
Aims: Iron deficiency (ID) is associated with an impaired cardiac function and remodelling in heart failure (HF). Treatment with ferric carboxymaltose (FCM) has been showed recently to improve biventricular systolic...
5.
Escobar-Cervantes C, Diez-Villanueva P, Bonanad Lozano C, Reino A, Almendro-Delia M, Facila L, et al.
Expert Rev Cardiovasc Ther
. 2023 Nov;
21(11):791-802.
PMID: 37933665
Introduction: In addition to an increased risk of thromboembolic complications, patients with atrial fibrillation (AF) are at risk for vascular events. Consequently, complete vascular protection is warranted in these patients....
6.
Escobar-Cervantes C, Reino A, Diez-Villanueva P, Facila L, Freixa-Pamias R, Valle A, et al.
Expert Rev Cardiovasc Ther
. 2023 Oct;
21(11):779-790.
PMID: 37874226
Introduction: Atrial fibrillation (AF) cannot be considered an isolated disease. Patients with AF should be managed using a comprehensive approach that is not limited to stroke prevention. Areas Covered: In...
7.
Minana G, Cordero A, Facila L, Company M, Fernandez-Cisnal A, Valero E, et al.
Am J Cardiol
. 2023 Oct;
211:9-16.
PMID: 37858663
Lipoprotein(a) (Lp[a]) is an emerging risk factor for incident ischemic heart disease. However, its role in risk stratification in in-hospital survivors to an index acute myocardial infarction (AMI) is scarcer,...
8.
Gorriz J, Gonzalez-Juanatey J, Facila L, Soler M, Valle A, Ortiz A
Nefrologia (Engl Ed)
. 2023 Oct;
43(4):386-398.
PMID: 37813743
Despite current treatments, which include renin angiotensin system blockers and SGLT2 inhibitors, the risk of progression of kidney disease among patients with diabetes and chronic kidney disease (CKD) remains unacceptably...
9.
Cordero A, Fernandez Olmo R, Badimon L, Santos-Gallego C, Castellano J, Facila L, et al.
J Clin Lipidol
. 2023 Sep;
17(5):602-611.
PMID: 37775463
Background: Statins are the cornerstone of lipid-lowering therapy (LLT) for reduction of low-density lipoprotein cholesterol (LDLc) levels and high percentage of patients require LLT combinations or alternative treatments for adequate...
10.
Cordero A, Fernandez Olmo R, Santos-Gallego C, Facila L, Bonanad C, Castellano J, et al.
Am J Cardiol
. 2023 Aug;
205:321-324.
PMID: 37633067
Bempedoic acid is a selective inhibitor of the adenosine triphosphate citrate lyase that reduces low-density lipoprotein cholesterol (LDLc) levels by 17% to 28%. Although the Evaluation of Major Cardiovascular Events...